BillionToOne is executing a high-growth strategy, with TTM revenue up 100% YoY and Q2 2026 revenue of $109.4M (+64.4% YoY), while gross margin expanded to 70.5%. The company achieved operating profitability in recent quarters, though Q2 2026 operating margin d...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.15-18.2% vs $0.18 | $109M+0.2% vs $109M |
Q2 2026 May 6, 2026 | $0.34+3300.0% vs $0.01 | $108M+11.6% vs $97M |
Q2 2026 Mar 4, 2026 | $0.11+57.1% vs $0.07 | $96M+10.2% vs $87M |
Q4 2025 Dec 9, 2025 | $0.10-28.3% vs $0.14 | $84M+0.7% vs $83M |
The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.
The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.
The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.
Benchmark BLLN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BillionToOne, Inc. (BLLN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $105.76 | $4.86B | 1660.28 | 99.97% | 2.44% | 2.3% | — | |
| $408.47 | $58.5B | -268.73 | 35.9% | -7.11% | -11.73% | — | |
| $265.72 | $40.2B | 48.76 | -0.78% | 18.36% | 31.08% | — | |
| $24.85 | $1.95B | 38.23 | 10.4% | 6% | 15.98% | — | |
| $66.23 | $3.42B | -165.58 | 13.79% | 24.23% | 32.81% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — |
BillionToOne, Inc. (BLLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BLLN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BillionToOne, Inc. (BLLN) stock FAQ — growth, dividends, profitability & financials explained
BillionToOne, Inc. (BLLN) reported $397.4M in revenue for fiscal year 2025. This represents a 454% increase from $71.7M in 2023.
BillionToOne, Inc. (BLLN) grew revenue by 100.0% over the past year. This is strong growth.
Yes, BillionToOne, Inc. (BLLN) is profitable, generating $33.5M in net income for fiscal year 2025 (2.4% net margin).
BillionToOne, Inc. (BLLN) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
BillionToOne, Inc. (BLLN) generated $33.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
